CO6260070A2 - Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c - Google Patents

Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c

Info

Publication number
CO6260070A2
CO6260070A2 CO10015824A CO10015824A CO6260070A2 CO 6260070 A2 CO6260070 A2 CO 6260070A2 CO 10015824 A CO10015824 A CO 10015824A CO 10015824 A CO10015824 A CO 10015824A CO 6260070 A2 CO6260070 A2 CO 6260070A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
nr10r11
nr11c
imidazopiridine
pains
Prior art date
Application number
CO10015824A
Other languages
English (en)
Inventor
Franz Ulrich Schmitz
Vincent W-F Tai
Roopa Rai
Christopher R Roberts
Ali Dehghani Abadi
Subramanian Baskaran
Irina Slobodov
Jack Maung
Martin Leon Nietzel
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CO6260070A2 publication Critical patent/CO6260070A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Al menos una entidad química seleccionada a partir de los compuestos de la fórmula 1:y las sales farmacéuticamente aceptables de los mismos, en donde: W1 se selecciona a partir de CR1 y NR1' W3 se selecciona a partir de CR3 y NR3 W4 se selecciona a partir de CR4 y N; W6 se selecciona a partir de CR6 y N; W8 se selecciona a partir de C y N; W9 se selecciona a partir de C y N; R1 está ausente o se selecciona a partir de hidrógeno, halógeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, amino opcionalmente sustituido, hetero-cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -OR15, -SR15, -S(O)R16, -S(O)2R16, -S(O)2NR10R11, -NR10R11, -NR11C(O)NR10R11, -NR11C(S)NR10R11, -NR11S(O)2R14, -NR11C(O)OR13, -NR11C(O)R12, -C(NR11)NR10R11, -C(O)NR10R11, -C(O)OR13, -CN, -NO2, y -C(O)R12; R2 se selecciona a partir de halógeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, amino opcionalmente sustituido, hetero-cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -OR15, -SR15, -S(O)R16, -S(O)2R16, -S(O)2NR10R11, -NR10R11, -NR11C(O)NR10R11, -NR11C(S)NR10R11, -NR11S(O)2R14, -NR11C(O)OR13, -NR11C(O)R12, -C(NR11)NR10R11, -C(O)NR10R11, -C(O)OR13, -CN, -NO2, y -C(O)R12; R3 está ausente o se selecciona a partir de hidrógeno, halógeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, amino opcionalmente sustituido, hetero-cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -OR15, -SR15, -S(O)R16, -S(O)2R15, -S(O)2NR10R11, -NR10R11, -NR11C(O)NR10R11, ...
CO10015824A 2007-08-10 2010-02-12 Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c CO6260070A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96422307P 2007-08-10 2007-08-10
US4108408P 2008-03-31 2008-03-31

Publications (1)

Publication Number Publication Date
CO6260070A2 true CO6260070A2 (es) 2011-03-22

Family

ID=39884633

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10015824A CO6260070A2 (es) 2007-08-10 2010-02-12 Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c

Country Status (15)

Country Link
US (2) US20120121540A1 (es)
EP (1) EP2187883A2 (es)
JP (1) JP2010535773A (es)
KR (1) KR20100053647A (es)
CN (1) CN101842098A (es)
AU (1) AU2008287421A1 (es)
BR (1) BRPI0814939A2 (es)
CA (1) CA2695989A1 (es)
CO (1) CO6260070A2 (es)
DO (1) DOP2010000052A (es)
EA (1) EA201000201A1 (es)
MX (1) MX2010001650A (es)
TW (1) TW200922569A (es)
WO (1) WO2009023179A2 (es)
ZA (1) ZA201001523B (es)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925902B1 (fr) * 2008-01-02 2011-01-07 Sanofi Aventis DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2334675B1 (en) 2008-09-16 2014-03-26 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
ME02418B (me) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibitori replikacije virusa hepatitisa c
KR20120023091A (ko) 2009-05-15 2012-03-12 노파르티스 아게 5-피리딘-3-일-1,3-디히드로-인돌-2-온 유도체, 및 알도스테론 신타제 및/또는 ｃｙｐ11ｂ1의 조절제로서의 그의 용도
CN102459247B (zh) 2009-05-15 2014-09-17 诺华股份有限公司 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2011041713A2 (en) * 2009-10-02 2011-04-07 Glaxosmithkline Llc Piperazinyl antiviral agents
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
WO2011097491A1 (en) * 2010-02-04 2011-08-11 Glaxosmithkline Llc Benzimidazole antiviral agents
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN102906089A (zh) * 2010-03-10 2013-01-30 百时美施贵宝公司 用于治疗丙型肝炎的化合物
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
WO2012008508A1 (ja) * 2010-07-14 2012-01-19 武田薬品工業株式会社 複素環化合物
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
HUE037937T2 (hu) 2010-07-29 2021-11-29 Oryzon Genomics Sa Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
AU2011320696B2 (en) 2010-10-26 2016-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US9422250B2 (en) 2011-04-08 2016-08-23 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US9029389B2 (en) * 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP2734186B1 (en) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Composition
MX2014001833A (es) 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
PE20141692A1 (es) 2011-10-20 2014-11-08 Oryzon Genomics Sa Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
PT2776439T (pt) 2011-11-09 2018-11-02 Janssen Sciences Ireland Uc Derivados de purina para o tratamento de infeções virais
WO2013100018A1 (ja) * 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
HUE060743T2 (hu) 2012-04-26 2023-04-28 Bristol Myers Squibb Co Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére
CN104540835B (zh) 2012-04-26 2017-08-08 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
JP6101343B2 (ja) 2012-04-26 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
CA2875057C (en) 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
AU2013288600B2 (en) 2012-07-13 2017-06-29 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
FR2993564B1 (fr) 2012-07-20 2014-08-22 Metabrain Res Derives d'imidazopyridine utiles dans le traitement du diabete
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CA2881995A1 (en) 2012-08-17 2014-02-20 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
UA114109C2 (xx) 2012-08-24 2017-04-25 Піразолопіримідинові сполуки
KR102217111B1 (ko) 2012-10-10 2021-02-18 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN104780924B (zh) 2012-11-20 2016-09-14 葛兰素史克有限责任公司 干扰素诱导剂化合物
PL2922549T3 (pl) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nowe związki
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
EP2939675B1 (en) * 2012-12-28 2019-09-04 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
EA202090547A3 (ru) 2013-03-29 2020-12-30 Янссен Сайенсиз Айрлэнд Юси Макроциклические деаза-оксипурины для лечения вирусных инфекций
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
ES2657283T3 (es) 2013-05-24 2018-03-02 Janssen Sciences Ireland Uc Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
US9249163B2 (en) 2013-06-11 2016-02-02 Janssen Pharmaceutica Nv. PDE10a inhibitors for the treatment of type II diabetes
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
SG10201803331PA (en) 2013-06-27 2018-06-28 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112016001570B1 (pt) 2013-07-30 2020-12-15 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas e composição farmacêutica que os compreende para o tratamento de infecções virais
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
US9108953B2 (en) 2013-11-26 2015-08-18 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
US9969687B2 (en) 2013-12-23 2018-05-15 Norgine B.V. Compounds useful as CCR9 modulators
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP4036094A1 (en) 2014-04-30 2022-08-03 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
WO2015169776A1 (en) 2014-05-08 2015-11-12 Bayer Cropscience Ag Pyrazolopyridine sulfonamides as nematicides
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
BR112017001334A2 (pt) 2014-08-06 2017-11-14 Pfizer compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
WO2016045587A1 (zh) * 2014-09-26 2016-03-31 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
WO2016071216A1 (en) 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
JP2018076234A (ja) * 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
CN107810188B (zh) 2015-04-08 2020-09-22 拜耳作物科学股份公司 作为害虫防治剂和中间体产物的稠合双环杂环衍生物
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
AU2016306555B2 (en) 2015-08-12 2021-01-28 Incyte Holdings Corporation Salts of an LSD1 inhibitor
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
DK3442977T3 (da) 2016-04-15 2023-10-09 Blueprint Medicines Corp Inhibitorer af activinreceptorlignende kinase
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168A (zh) * 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
PE20190800A1 (es) 2016-08-15 2019-06-10 Bayer Cropscience Ag Derivados del heterociclo biciclico condensado como agentes de control de plagas
AU2017335205B2 (en) 2016-09-29 2021-11-04 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
KR20230020566A (ko) 2017-01-10 2023-02-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
EP3568392B1 (de) 2017-01-10 2021-02-24 Bayer Aktiengesellschaft Imidazol-derivate als schädlingsbekämpfungsmittel
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited CONNECTION WITH CYCLICAL STRUCTURE
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
MX2020003604A (es) 2017-10-04 2020-07-28 Bayer Ag Derivados heterociclicos como pesticidas.
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
JP7305658B2 (ja) 2018-01-31 2023-07-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
WO2019162174A1 (de) 2018-02-21 2019-08-29 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019175045A1 (de) 2018-03-12 2019-09-19 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
MX2020011061A (es) 2018-04-20 2020-11-06 Bayer Ag Derivados de heterocicleno como agentes para el control de plagas.
AU2019260109B2 (en) 2018-04-23 2023-07-13 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
BR112020021612A2 (pt) 2018-05-17 2021-01-26 Bayer Aktiengesellschaft derivados substituídos de di-hidropirazolo pirazina carboxamida
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220235057A1 (en) * 2019-05-14 2022-07-28 Nanjing Tech University Cyclic formyl and cyclic ketone compounds, preparation method therefor, and pharmaceutical use
WO2021055621A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors and uses thereof
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN114599366A (zh) 2019-09-19 2022-06-07 托特斯医药公司 治疗性缀合物
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4225742A1 (en) 2020-10-05 2023-08-16 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2022087422A1 (en) * 2020-10-22 2022-04-28 Chulalongkorn University Pyrrolidine-3-carboxamide derivatives and related uses
EP4267574A1 (en) 2020-12-23 2023-11-01 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
CN117402156A (zh) * 2022-07-08 2024-01-16 中国科学院上海药物研究所 一类酰胺化合物及其制备方法、药物组合物和用途
WO2024145569A2 (en) 2022-12-30 2024-07-04 Avicenna Biosciences, Inc. Azaindole rock inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS5229318B2 (es) * 1972-03-30 1977-08-01
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE355380T1 (de) * 1993-04-02 2006-03-15 Rigel Pharmaceuticals Inc Methode zur selektiven inaktivierung der viralen replication
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JP2004502640A (ja) * 2000-02-10 2004-01-29 ニューヨーク・ユニバーシティ 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008514622A (ja) * 2004-09-24 2008-05-08 スミスクライン ビーチャム コーポレーション 化合物
WO2006054143A1 (en) * 2004-11-17 2006-05-26 Pfizer Inc. Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
JP2008531596A (ja) * 2005-02-25 2008-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染を治療または予防するのに有用なベンゾイソチアゾール
WO2006109633A1 (ja) * 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7807838B2 (en) * 2005-08-24 2010-10-05 Pfizer Inc. Methods for the preparation of HCV polymerase inhibitors
EP1959737A4 (en) * 2005-12-16 2010-12-08 Glaxosmithkline Llc CHEMICAL COMPOUNDS
EP1968580A2 (en) * 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
WO2007071434A1 (en) * 2005-12-22 2007-06-28 Smithkline Beecham Corporation Antiviral 2-carboxy-thiophene compounds
EP2010172B1 (en) * 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
CA2668959A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives

Also Published As

Publication number Publication date
ZA201001523B (en) 2011-05-25
MX2010001650A (es) 2010-08-02
US20090176778A1 (en) 2009-07-09
TW200922569A (en) 2009-06-01
KR20100053647A (ko) 2010-05-20
WO2009023179A2 (en) 2009-02-19
JP2010535773A (ja) 2010-11-25
WO2009023179A3 (en) 2009-08-06
US20120121540A1 (en) 2012-05-17
BRPI0814939A2 (pt) 2015-01-27
CA2695989A1 (en) 2009-02-19
DOP2010000052A (es) 2010-03-31
EA201000201A1 (ru) 2010-12-30
AU2008287421A1 (en) 2009-02-19
CN101842098A (zh) 2010-09-22
EP2187883A2 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
CO6260070A2 (es) Entidades quimicas de imidazopiridina paea el tratamiento de infecciones con hepatitis c
NO20050065L (no) Kjemiske forbindelser
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
DE60315615D1 (de) Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
MA29742B1 (fr) Derives de benzoquinazoline et utilisation de ceux-ci dans le traitement de maladies osseuses
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
BRPI0607817B8 (pt) compostos macrocíclicos e seu processo de preparação
ATE433981T1 (de) Heterocyclische verbindungen
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
AR035436A1 (es) Una benzofenona o derivado farmaceuticamente aceptable, sales, formas salinas, composiciones farmaceuticas, usos para la fabricacion de un medicamento, y proceso para la preparacion de una benzofenona
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
DK1987025T3 (da) Benzoxazinon og benzoxazepinonoxazolidinoner som antibakterielle midler
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
PE20040531A1 (es) Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen
DE602005010607D1 (de) Zyklosporinanalog
BRPI0918966A8 (pt) composto inibidor de proteases, composição farmacêutica compreendendo dito compostos e uso terapêutico do mesmo
RU2003113145A (ru) Замещенные 5r1, 6r2-1, 3,4-тиадиазин-2, амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулятным и антиагрегатным действием
NO20075505L (no) 7-fluor-1,3-dihydro-indol-2-on oksazolidinoner som antibakterielle forbindelser
AR070697A1 (es) Derivados heterociclicos que contienen nitrogeno y composiciones farmaceuticas que los contienen
NO20075547L (no) Et oksindol oksazolidinon som et antibakterielt middel
PE20231095A1 (es) Herbicidas de haloalquilsulfonanilida sustituida
TH53986A (th) ซัลโฟนิลออกซาโซลามีนชนิดใหม่
TH87496B (th) สารประกอบใหม่
TH62190A (th) สารประกอบอินทรีย์
TH65185A (th) การใช้สารยับยั้ง IkB- ไคเนส ในการรักษาอาการเจ็บปวด

Legal Events

Date Code Title Description
FA Application withdrawn